Abstract:Abstract Background: Genetic testing for patients with breast cancer (BCa) patients may change the routine patient care and shift the paradigm towards more personalized managing and treatment strategies. In particular, testing germline mutations in BRCA1/2 has become a part of the standard clinical practice for patients with BCa. However, our understanding of genetic epidemiology of BCa is mainly driven by data from Caucasian populations and it has been evident that gene alterations may be ethnic specific in breast cancer. Methods: Aiming to delineate the landscape of germline mutations in Chinese patients with BCa to breast cancer, we collected blood samples from in 356 BCa patients at stage I-IV in Beijing Cancer Hospital between Jan. 2013 to Dec. 2019. Peripheral blood mononuclear cells were isolated from blood samples and genomic DNA were extracted for capture-based NGS sequencing. A large comprehensive 600 gene panel (PredicineATLAS, Huidu Medical Science Techonology, Inc.) was used to detect germline mutations in the covered genes with average 300x sequencing depth. Results: A total of 356 BCa patients were included in our study, with the median age at first diagnosis of 49 years (Range: 21-87). Among all cases, 21.9% (78/356, 95% confidence interval [CI]: 17.7-26.6%) carried pathogenic or likely pathogenic mutations in 48 cancer related genes. Twenty-seven patients (7.6%, 95% CI: 5.1-10.8%) harbored BRCA1/2 mutations, followed by 5 patients carrying ATM mutations and RAD50 mutations respectively. Other commonly mutated genes include BARD1 (1.1%), FANCD2 (1.1%), CHEK2 (0.6%), FANCC (0.6%), FANCM (0.6%), PMS2 (0.6%), and TP53 (0.6%), most of which are related to DNA damage repair pathway. Moreover, BRCA1/2 carriers were more likely to appear among those with breast or ovarian cancer family history than those without (OR=3.41, 95% CI: 1.14-9.12, P=0.01). Compared with patients that aged older than 50 years at first diagnosis, those aged 30 years or younger were 6 times more likely to detect germline mutations in BRCA1/2 (95% CI: 1.18-26.1, P=0.02). In addition, mutations in BRCA1/2 were differentially associated with breast cancer subtypes. BRCA1 mutations were strongly enriched in triple-negative breast cancer (TNBC) (OR=6.7, 95% CI: 1.54-33.13, P=0.005). There is no strong significant survival difference observed between BRCA1/2 carriers and non-carriers, however, patients carrying ATM or RAD50 mutations tend to have lower disease-free survival. Conclusions: This is a comprehensive analysis of germline mutation spectrum in a large Chinese patient cohort with breast cancer. Collectively, a substantial proportion of patients with breast cancer had hereditary risk factors. Distinct distribution of pathogenic mutations in breast cancer subtypes and differential associations between mutation status and clinical features were further observed. All these findings will advance our understanding regarding the pathologies and heterogeneity of breast cancer. Citation Format: Nan Wang, Jiayang Zhang, Lu Tan, Hao Liao, Yaxin Liu, Xinyu Gui, Jiaxin Niu, Feng Xie, Yue Zhang, Yong Huang, Jianjun Yu, Huiping Li. Germline mutation landscape in Chinese breast cancer patients [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS16-08.

853P the Germline Mutation Landscape of DDR Genes in Chinese Patients with Epithelial Ovarian Cancer

Identification of <i>BRCA1</i>:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Characteristics of Germline DNA Damage Response Gene Mutations in Ovarian Cancer in Southwest China.

Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics

Germline Mutational Landscape in Chinese Patients with Advanced Breast Cancer

Brca1 And Brca2 Mutations In Ovarian Cancer Patients From China: Ethnic-Related Mutations In Brca1 Associated With An Increased Risk Of Ovarian Cancer

Brca1 And Brca2 Mutations In Ovarian Cancer Patients From China: Association Of Ethnic-Specific Mutations In Brca1 With An Increased Risk Of Ovarian Cancer

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.

Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients with Ovarian Cancer

Retrospective analysis of non-BRCA gene pathogenicity variation in Chinese patients with ovarian cancer.

Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer

Germline and Tumor BRCA1/2 Mutations in Chinese High Grade Serous Ovarian Cancer Patients.

The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.

EP1029 A Preliminary Study of Genetic Susceptibility and Treatment Related Gene Profiling in Chinese Ovarian Cancer Patients

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Abstract PS16-08: Germline Mutation Landscape in Chinese Breast Cancer Patients

BRCA Germline Mutations in an Unselected Nationwide Cohort of Chinese Patients with Ovarian Cancer and Healthy Controls

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

Mutation characteristics of cancer susceptibility genes in Chinese ovarian cancer patients

[BRCA1 Germ Line Mutations in Chinese Early-Onset Breast Cancer Patients].